{
    "nct_id": "NCT04639050",
    "title": "A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "last_update_time": "2025-07-04",
    "description_brief": "The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1",
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "RO7126209 (trontinemab) \u2014 a bispecific monoclonal antibody (gantenerumab-derived 'brain\u2011shuttle' that binds A\u03b2 plaques and the transferrin receptor to enhance BBB uptake)"
    ],
    "placebo": [
        "RO7126209\u2011matching placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests RO7126209 (trontinemab) administered IV in amyloid PET\u2013positive AD patients and measures change in brain amyloid load and pharmacodynamics, indicating a therapy directed at Alzheimer\u2019s pathology (amyloid). \ue200cite\ue202turn0search3\ue202turn1search1\ue201",
        "Act: Public sources identify RO7126209 as trontinemab, a bispecific monoclonal antibody engineered from gantenerumab with a transferrin\u2011receptor (TfR1) binding 'brain shuttle' to increase brain penetration and target A\u03b2 plaques \u2014 i.e., an anti\u2011amyloid immunotherapy (biologic). Trial entries and reviews describe amyloid PET endpoints and dosing regimens for plaque clearance. \ue200cite\ue202turn1search3\ue202turn1search2\ue202turn1search1\ue201",
        "Reflect: Classification as 'disease\u2011targeted biologic' matches the intervention type (monoclonal antibody immunotherapy) and intended effect (amyloid removal/disease modification). There is no indication this is a symptomatic cognitive enhancer or neuropsychiatric treatment; diagnostic imaging is used for selection, not as the intervention, so 'N/A' is not appropriate. Sources: clinical trial registry and Roche/clinical summaries and independent review. \ue200cite\ue202turn0search3\ue202turn1search3\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug RO7126209 (trontinemab) is a gantenerumab-derived, bispecific monoclonal antibody engineered to bind amyloid\u2011beta (A\u03b2) plaques while using a transferrin\u2011receptor 'brain shuttle' to enhance blood\u2013brain barrier uptake \u2014 the intended therapeutic action is clearance/reduction of brain amyloid, so the biological focus is amyloid\u2011beta. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act: Extracted details \u2014 trial registry and company pages identify RO7126209 as trontinemab (gantenerumab\u2011derived brain\u2011shuttle antibody) administered IV in amyloid PET\u2013positive AD patients and report amyloid PET and CSF/plasma AD biomarker changes as pharmacodynamic endpoints (i.e., anti\u2011amyloid immunotherapy aimed at plaque removal). Based on these explicit targets and endpoints, assign: A) Amyloid beta. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search7\ue201",
        "Reflect: Confirmation and nuance \u2014 the bispecific antibody also binds the transferrin receptor to increase brain delivery, but that interaction is a delivery mechanism (BBB shuttle), not the primary disease target; therefore the correct CADRO classification is A) Amyloid beta rather than multi\u2011target or Other. Trial sources and press releases showing rapid, dose\u2011dependent PET amyloid lowering support this. \ue200cite\ue202turn0search3\ue202turn0search7\ue201",
        "Web search results (key sources used): ClinicalTrials.gov trial entry for NCT04639050 (RO7126209 / trontinemab; study design, amyloid\u2011positive enrollment, drug synonyms). \ue200cite\ue202turn0search0\ue201; ALZFORUM therapeutic overview describing trontinemab as gantenerumab fused to a transferrin\u2011receptor binding brain shuttle and targeting amyloid plaques. \ue200cite\ue202turn0search3\ue201; Roche / ForPatients trial summary describing study parts, IV dosing and amyloid\u2011positive selection. \ue200cite\ue202turn0search2\ue201; Roche press release and coverage reporting PET amyloid reductions and biomarker effects with trontinemab. \ue200cite\ue202turn0search7\ue202turn0news12\ue201"
    ]
}